New Imaging Data Show XPro's Early Brain Microstructure Effects in Alzheimer's
INMB sits 64% above its 52-week low of $1.09.
Summary
INmune Bio will present new Phase 2 imaging data for XPro in early Alzheimer's at AAIC, showing statistically significant treatment effects on white matter myelin integrity (p<0.01) and concordant cortical microstructure changes at Week 24. The findings, using independent MRI methods, support early biologic activity of selective soluble TNF inhibition and reinforce target engagement. This follows the June 2 positive topline results and adds mechanistic validation ahead of the July 12 poster presentation. The data strengthen the case for XPro's potential in Alzheimer's, though the company's going concern warning and recent dilutive financing remain key risks.
At the time of this announcement, INMB was trading at $1.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45.7M. The 52-week trading range was $1.09 to $3.24. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.